2021年美国风湿病学会/血管炎基金会川崎病管理指南
该指南针对风湿免疫科常被咨询的川崎病(KD)诊疗场景,围绕诊断检查、治疗和管理提出16个PICO临床问题,经系统文献综述和GRADE方法评估证据质量并形成推荐,最终给出1条良好实践声明、11条推荐和1条未分级立场声明,其中7条强推荐、4条条件推荐。
要点
- 所有川崎病患者均应接受静脉注射免疫球蛋白(IVIG)初始治疗(良好实践声明)。
- 强推荐包括:及时治疗不完全川崎病、使用阿司匹林、不明原因巨噬细胞活化综合征或休克时行超声心动图。
- 条件推荐包括:对IVIG抵抗和/或冠状动脉瘤高危特征患者,IVIG联合其他辅助药物。
核心结论
- 这些推荐为疑似或确诊川崎病患者的诊断策略、药物使用和超声心动图应用提供指导。
研究设计与样本
- 由美国风湿病学会/血管炎基金会制定,围绕16个PICO临床问题开展系统文献综述,采用GRADE方法评估证据质量并形成推荐,每条推荐需至少70%投票委员会成员达成共识。
主要发现
- 共提出1条良好实践声明、11条推荐和1条未分级立场声明,聚焦于其他管理专科可能请求风湿免疫科会诊的场景,如治疗难治性、严重或复杂性川崎病。
- 良好实践声明确认所有川崎病患者均应接受IVIG初始治疗。
- 制定了7条强推荐和4条条件推荐用于川崎病或疑似川崎病的管理。
- 强推荐包括及时治疗不完全川崎病、使用阿司匹林、在不明原因巨噬细胞活化综合征或休克时行超声心动图。
- 条件推荐包括对具有IVIG抵抗和/或冠状动脉瘤高危特征的患者使用IVIG联合其他辅助药物。
关键数值与推荐
- 良好实践声明:所有川崎病患者均应接受IVIG初始治疗。
- 强推荐:及时治疗不完全川崎病。
- 强推荐:使用阿司匹林。
- 强推荐:在不明原因巨噬细胞活化综合征或休克时行超声心动图。
- 条件推荐:对具有IVIG抵抗和/或冠状动脉瘤高危特征的患者,使用IVIG联合其他辅助药物。
临床怎么用
- 原文未据此给出推荐,仅复述指南结论:这些推荐为疑似或确诊川崎病患者的诊断策略、药物使用和超声心动图应用提供指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. METHODS: Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. RESULTS: We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. CONCLUSION: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
引用
- Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Rheumatol. 2022. PMID: 35257501. doi:10.1002/art.42041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。